The Medicines and Healthcare products Regulatory Agency (MHRA) has proposed future amendments to the Medical Devices Regulations 2002 (MDR 2002). These amendments would introduce common specifications requirements for high-risk in-vitro diagnostic (IVD) devices, aiming to align with the General Safety and Performance Requirements (GSPR) of the In Vitro Diagnostic Regulation (IVDR). This initiative includes specific requirements for COVID-19 test devices as part of the Medical Device Regulations 2021.
The common specifications concept is akin to the common technical specifications already applicable to certain high-risk IVD devices under the current MDR 2002. The proposed amendments will update the IVD classification system to a risk-based approach, categorizing devices from Class A (lowest risk) to Class D (highest risk). MHRA proposes to implement Common Specifications requirements for specific Class D IVD devices under future regulations.
Proposal Highlights:
1. Introduction of Common Specifications for Class D IVD Devices:
-
-
- Align with EU Commission Implementing Regulation 2022/1107.
-
2. Incorporation into Post Market Performance Follow-Up (PMPF):
-
-
- Include Common Specification requirements as part of the PMPF process.
-
3. Removal of COVID-19 Test Device Requirements from MDR 2002:
-
-
- Avoid regulatory duplication, ensuring manufacturers only comply with Common Specifications for SARS-CoV-2 tests instead of the Coronavirus Test Device Approvals requirements in MDR 2002.
-
For further details, you can access the full consultation document, which includes the consultation questions at the end: Consultation Document: Common Specification Requirements for In Vitro Diagnostic Devices.
Stay informed on the latest regulatory updates by following our website.
______________________________________________
If you have any question about the MHRA’s proposed future amendments to common specifications requirements for high-risk in-vitro diagnostic (IVD) devices, contact us so our consultants can assist you.